Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Effect of mannitol-based reduced-volume hydration on kidney function in concomitant cisplatin-based chemoradiation for head-and-neck squamous cell carcinoma.

Author information

Affiliations

  • 1. Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
      Authors
    • Paschen C 1, 2
    • Hecking M 1
    (2 authors)
  • 2. Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
      Authors
    • Paschen C 1, 2
    • Moll M 2
    • Altorjai G 2
    • Widder J 2
    • Herrmann H 2
    (5 authors)
  • 3. Division of Oncology, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
      Authors
    • Fuereder T 3
    (1 author)

ORCIDs linked to this article

Head & Neck, 22 Jun 2023, 45(8):2087-2097
https://doi.org/10.1002/hed.27438 PMID: 37345576 

Abstract 

Objective

Nephrotoxicity is frequent in cisplatin-based chemoradiation of head and neck squamous cell carcinoma (HNSCC). Toxicity outcomes and achieved cisplatin-doses after change of departmental hydration policy are presented.

Methods

We performed a retrospective time-series analysis of HNSCC patients undergoing chemoradiation with conventional hydration (CH) between 01/2017 and 09/2018 versus shorter hydration with mannitol (SHM) between 09/2018 and 08/2019 to compare the rate of acute kidney injury (AKI) and cumulative cisplatin dose.

Results

Among 113 HNSCC patients, SHM (n = 35) in comparison to CH (n = 78) correlated with less AKI (54.3% vs. 74.4%; p = 0.034) and higher cisplatin doses (82.9% vs. 61.5% ≥200 mg/m2 ; p = 0.025). AKI ≥grade 2 was lower with SHM (2.9% vs. CH: 22.8%; p = 0.01). AKI occurred more frequently in females (92.6% vs. males: 60.5%, p = 0.002). Females received lower cumulative cisplatin doses (51.9% vs. males: 73.3%; p = 0.037).

Conclusions

We observed less AKI and higher cumulative chemotherapy doses with SHM. Female patients were at higher risk of AKI.

Full text links 

Read article at publisher's site: https://doi.org/10.1002/hed.27438

Read article for free, from open access legal sources, via Unpaywall: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hed.27438Unpaywall

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.